Literature DB >> 26761545

Evaluation of Xpert HIV-1 Qual assay for resolution of HIV-1 infection in samples with negative or indeterminate Geenius HIV-1/2 results.

Michal Michaeli1, Marina Wax1, Yael Gozlan1, Aviya Rakovsky1, Ella Mendelson2, Orna Mor3.   

Abstract

BACKGROUND: Diagnosis of HIV infection is a multistage algorithm. Following screening with 4(th) generation combination immunoassay, confirmation of HIV infection is performed with an antibody assay that differentiates HIV-1 from HIV-2 infection. In the newly updated algorithm, samples that are nonreactive or indeterminate in the differentiation assay are to be tested with an HIV-1 nucleic acid amplification (NAAT) test for resolution. Xpert HIV-1 Qual is a new NAAT assay approved for the identification of HIV infection in whole and dried blood.
OBJECTIVES: To assess the performance of Xpert HIV-1 Qual supplementary assay in resolving the clinical status of serum samples reactive by 4(th) generation immunoassays and indeterminate or negative by Geenius HIV-1/2 confirmatory assay. STUDY
DESIGN: In a retrospective study, samples from 97 individuals for whom the true HIV-1 status was already known (by follow-up samples) and which were negative or indeterminate by HIV-1/2 Geenius assay were tested with Xpert Qual HIV-1 assay.
RESULTS: Xpert Qual assay correctly classified all 97 samples from HIV-1 positive (n=49) and negative (n=48) individuals. The sensitivity and specificity of Xpert Qual when using the true HIV status as a reference were 100% (92.7-100% at 95% confidence interval [CI] and 92.6-100% at 95% CI, respectively).
CONCLUSIONS: Applying Xpert Qual HIV-1 assay in the new HIV multi-stage diagnostic algorithm correctly classified 100% of HIV-1 infections including 49 from HIV-1 carriers who have not yet seroconverted. With this assay the total time required for acute HIV diagnosis could be significantly reduced.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Geenius; HIV-1 Qual; HIV-1/2 infection; NAAT; Xpert

Mesh:

Substances:

Year:  2015        PMID: 26761545     DOI: 10.1016/j.jcv.2015.12.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa.

Authors:  Lesley Scott; Anura David; Lara Noble; Matilda Nduna; Pedro Da Silva; Andrew Black; Francois Venter; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

2.  Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.

Authors:  Roy Moscona; Daniela Ram; Marina Wax; Efrat Bucris; Itzchak Levy; Ella Mendelson; Orna Mor
Journal:  J Int AIDS Soc       Date:  2017-08-10       Impact factor: 5.396

Review 3.  Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.

Authors:  Sarah E Rutstein; Jintanat Ananworanich; Sarah Fidler; Cheryl Johnson; Eduard J Sanders; Omar Sued; Asier Saez-Cirion; Christopher D Pilcher; Christophe Fraser; Myron S Cohen; Marco Vitoria; Meg Doherty; Joseph D Tucker
Journal:  J Int AIDS Soc       Date:  2017-06-28       Impact factor: 5.396

4.  Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care.

Authors:  Clara A Agutu; Caroline J Ngetsa; Matt A Price; Tobias F Rinke de Wit; Gloria Omosa-Manyonyi; Eduard J Sanders; Susan M Graham
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

5.  CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.

Authors:  Michele Lai; Eyal Maori; Paola Quaranta; Giulia Matteoli; Fabrizio Maggi; Marco Sgarbanti; Stefania Crucitta; Simone Pacini; Ombretta Turriziani; Guido Antonelli; Jonathan L Heeney; Giulia Freer; Mauro Pistello
Journal:  J Virol       Date:  2021-09-22       Impact factor: 5.103

Review 6.  Point of Care Diagnostics for HIV in Resource Limited Settings: An Overview.

Authors:  Sello Lebohang Manoto; Masixole Lugongolo; Ureshnie Govender; Patience Mthunzi-Kufa
Journal:  Medicina (Kaunas)       Date:  2018-03-13       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.